Antibody Response to Human Papillomaviruses in Women
Author Information
Author(s): Giorgi Colomba, Di Bonito Paola, Grasso Felicia, Mochi Stefania, Accardi Luisa, Donà Maria Gabriella, Branca Margherita, Costa Silvano, Mariani Luciano, Agarossi Alberto, Ciotti Marco, Syrjänen Kari
Primary Institution: Istituto Superiore di Sanità, Roma, Italy
Hypothesis
What are the clinical and epidemiological correlates of HPV-seroreactivity in HIV-negative and HIV-positive women?
Conclusion
HIV-positive current smokers are a high-risk group with significantly impaired immunological response to HPV, which may contribute to the development of cervical cancer.
Supporting Evidence
- HIV-positive women showed significantly less antibody response compared to HIV-negative women.
- Current smokers had significantly lower seroreactivity to L antigens.
- The association between smoking and lower seroreactivity remained significant even when controlled for age.
Takeaway
This study found that women who smoke and are HIV-positive have a much harder time fighting off HPV infections, which can lead to serious health problems.
Methodology
The study used an ELISA test to evaluate seroreactivity to HPV16 antigens in a cohort of women and correlated the results with their clinical and epidemiological data.
Potential Biases
Potential bias due to the small number of HIV-positive women and their similar HPV baseline status to HIV-negative women.
Limitations
The small sample size may limit the power to detect true differences in age and other variables.
Participant Demographics
The study included HIV-negative and HIV-positive women, with a focus on their smoking status and HPV exposure.
Statistical Information
P-Value
p = 0.014
Confidence Interval
95%CI 0.036–0.695
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website